Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 1/20 | 0.59 |
| ▸ | CD2 | P06729 | 1/20 | 0.53 |
| ▸ | CD58 | P19256 | 1/20 | 0.53 |
| ▸ | MLNR | O43193 | 12/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | GRB2 | P62993 | 1/20 | 0.46 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.44 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23968131 | 1.00 | OXTR (0.59) | OXTRCD2CD58MLNROPRM1 | |
| SCHEMBL22844368 | 0.94 | OXTR (0.58) | OXTRCD2CD58MLNROPRM1 | |
| SCHEMBL21312758 | 0.94 | OXTR (0.58) | OXTRCD2CD58MLNROPRM1 | |
| SCHEMBL22618582 | 0.87 | SSTR2 (0.56) | OXTRCD2CD58OPRM1OPRD1 | |
| SCHEMBL23968133 | 0.87 | SSTR2 (0.56) | OXTRCD2CD58OPRM1OPRD1 | |
| SCHEMBL22618578 | 0.87 | SSTR2 (0.56) | OXTRCD2CD58OPRM1OPRD1 | |
| SCHEMBL20465752 | 0.81 | SSTR2 (0.69) | SSTR2SSTR5 | |
| SCHEMBL19682057 | 0.80 | OXTR (0.52) | OXTRCD2CD58MLNROPRM1 | |
| SCHEMBL26814255 | 0.78 | SSTR2 (0.54) | SSTR2SSTR5 | |
| SCHEMBL20091616 | 0.78 | OXTR (0.77) | OXTROPRM1OPRD1OPRK1GRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3473630-B1 | BORON-BASED PRODRUG STRATEGY FOR INCREASED BIOAVAILABILITY AND LOWER-DOSAGE REQUIREMENTS FOR DRUG MOLECULES CONTAINING AT LEAST ONE PHENOL (OR AROMATIC HYDROXYL) GROUP | XAVIER UNIV OF LOUISIANA (US) | 2021-01-13 | — | — | EP | disclosed |